FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151843249> ?p ?o ?g. }

• W2151843249 endingPage "1565" @default.
• W2151843249 startingPage "1557" @default.
• W2151843249 abstract "// Ophélie Cassuto 1 - 4* , Maeva Dufies 1 - 2* , Arnaud Jacquel 1 - 2 , Guillaume Robert 1 - 2 , Clémence Ginet 1 - 2 , Alix Dubois 1 - 2 , Amine Hamouda 1 - 2 , Alexandre Puissant 1,2 ,# , Fredéric Luciano 1 - 2 , Jean-Michel Karsenti 3 , Laurence Legros 3 , Jill Patrice Cassuto 3 , Pascal Lenain 4 , Patrick Auberger 1 - 3 1 C3M/ INSERM U1065 Team Cell Death, Differentiation, Inflammation and Cancer, Nice, France 2 Equipe Labellisée Ligue Nationale contre le Cancer 2011-2013, Paris, France 3 Service d’Hématologie Clinique et de Transplantation, CHU de Nice, France 4 Centre Henri Becquerel, CLCC, Rouen, France # Dana-Farber Cancer Institute, Pediatric-Oncology department, 450 Brookline Avenue, Boston, MA, USA * denotes equal contribution Correspondence: Patrick Auberger, email: // Keywords : CML, BCR ABL, TKI, Resistance, Ponatinib Received : October 02, 2012, Accepted : November 12, 2012, Published : November 14, 2012 Abstract The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL by imatinib, dasatinib or nilotinib triggers durable responses in most patients suffering from this disease. Moreover, resistance to imatinib due to kinase domain mutations can be generally circumvented using dasatinib or nilotinib, but the multi-resistant T315I mutation that is insensitive to these TKIs, remains to date a major clinical problem. In this line, ponatinib (AP24534) has emerged as a promising therapeutic option in patients with all kinds of BCR-ABL mutations, especially the T315I one. However and surprisingly, the effect of ponatinib has not been extensively studied on imatinib-resistant CML cell lines. Therefore, in the present study, we used several CML cell lines with different mechanisms of resistance to TKI to evaluate the effect of ponatinib on cell viability, apoptosis and signaling. Our results show that ponatinib is highly effective on both sensitive and resistant CML cell lines, whatever the mode of resistance and also on BaF3 murine B cells carrying native BCR-ABL or T315I mutation. We conclude that ponatinib could be effectively used for all types of TKI-resistant patients." @default.
• W2151843249 created "2016-06-24" @default.
• W2151843249 creator A5001228294 @default.
• W2151843249 creator A5007084558 @default.
• W2151843249 creator A5019869704 @default.
• W2151843249 creator A5029424482 @default.
• W2151843249 creator A5034528977 @default.
• W2151843249 creator A5037025946 @default.
• W2151843249 creator A5038903944 @default.
• W2151843249 creator A5038965613 @default.
• W2151843249 creator A5039959145 @default.
• W2151843249 creator A5051365781 @default.
• W2151843249 creator A5066167524 @default.
• W2151843249 creator A5068342352 @default.
• W2151843249 creator A5077255086 @default.
• W2151843249 creator A5084855457 @default.
• W2151843249 date "2012-11-14" @default.
• W2151843249 modified "2023-10-11" @default.
• W2151843249 title "All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib" @default.
• W2151843249 cites W1851477645 @default.
• W2151843249 cites W1901739712 @default.
• W2151843249 cites W1969539549 @default.
• W2151843249 cites W1993675254 @default.
• W2151843249 cites W1995552866 @default.
• W2151843249 cites W2011043590 @default.
• W2151843249 cites W2053174681 @default.
• W2151843249 cites W2055001622 @default.
• W2151843249 cites W2056395592 @default.
• W2151843249 cites W2070881021 @default.
• W2151843249 cites W2073758210 @default.
• W2151843249 cites W2094087619 @default.
• W2151843249 cites W2102182628 @default.
• W2151843249 cites W2110648386 @default.
• W2151843249 cites W2110803599 @default.
• W2151843249 cites W2122132017 @default.
• W2151843249 cites W2123853229 @default.
• W2151843249 cites W2136065656 @default.
• W2151843249 cites W2139910235 @default.
• W2151843249 cites W2167770231 @default.
• W2151843249 cites W2168576472 @default.
• W2151843249 doi "https://doi.org/10.18632/oncotarget.692" @default.
• W2151843249 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3681494" @default.
• W2151843249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23238683" @default.
• W2151843249 hasPublicationYear "2012" @default.
• W2151843249 type Work @default.
• W2151843249 sameAs 2151843249 @default.
• W2151843249 citedByCount "32" @default.
• W2151843249 countsByYear W21518432492013 @default.
• W2151843249 countsByYear W21518432492014 @default.
• W2151843249 countsByYear W21518432492015 @default.
• W2151843249 countsByYear W21518432492016 @default.
• W2151843249 countsByYear W21518432492017 @default.
• W2151843249 countsByYear W21518432492018 @default.
• W2151843249 countsByYear W21518432492019 @default.
• W2151843249 countsByYear W21518432492020 @default.
• W2151843249 countsByYear W21518432492021 @default.
• W2151843249 countsByYear W21518432492022 @default.
• W2151843249 countsByYear W21518432492023 @default.
• W2151843249 crossrefType "journal-article" @default.
• W2151843249 hasAuthorship W2151843249A5001228294 @default.
• W2151843249 hasAuthorship W2151843249A5007084558 @default.
• W2151843249 hasAuthorship W2151843249A5019869704 @default.
• W2151843249 hasAuthorship W2151843249A5029424482 @default.
• W2151843249 hasAuthorship W2151843249A5034528977 @default.
• W2151843249 hasAuthorship W2151843249A5037025946 @default.
• W2151843249 hasAuthorship W2151843249A5038903944 @default.
• W2151843249 hasAuthorship W2151843249A5038965613 @default.
• W2151843249 hasAuthorship W2151843249A5039959145 @default.
• W2151843249 hasAuthorship W2151843249A5051365781 @default.
• W2151843249 hasAuthorship W2151843249A5066167524 @default.
• W2151843249 hasAuthorship W2151843249A5068342352 @default.
• W2151843249 hasAuthorship W2151843249A5077255086 @default.
• W2151843249 hasAuthorship W2151843249A5084855457 @default.
• W2151843249 hasBestOaLocation W21518432491 @default.
• W2151843249 hasConcept C126322002 @default.
• W2151843249 hasConcept C143998085 @default.
• W2151843249 hasConcept C2776960273 @default.
• W2151843249 hasConcept C2777413986 @default.
• W2151843249 hasConcept C2777583451 @default.
• W2151843249 hasConcept C2778461978 @default.
• W2151843249 hasConcept C2778729363 @default.
• W2151843249 hasConcept C2779536868 @default.
• W2151843249 hasConcept C2780381907 @default.
• W2151843249 hasConcept C3019892230 @default.
• W2151843249 hasConcept C71924100 @default.
• W2151843249 hasConceptScore W2151843249C126322002 @default.
• W2151843249 hasConceptScore W2151843249C143998085 @default.
• W2151843249 hasConceptScore W2151843249C2776960273 @default.
• W2151843249 hasConceptScore W2151843249C2777413986 @default.
• W2151843249 hasConceptScore W2151843249C2777583451 @default.
• W2151843249 hasConceptScore W2151843249C2778461978 @default.
• W2151843249 hasConceptScore W2151843249C2778729363 @default.
• W2151843249 hasConceptScore W2151843249C2779536868 @default.
• W2151843249 hasConceptScore W2151843249C2780381907 @default.
• W2151843249 hasConceptScore W2151843249C3019892230 @default.
• W2151843249 hasConceptScore W2151843249C71924100 @default.
• W2151843249 hasIssue "12" @default.
• W2151843249 hasLocation W21518432491 @default.

• next